# Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)

> **NCT05996263** · — · UNKNOWN · sponsor: **University Hospital, Brest** · enrollment: 75 (estimated)

## Conditions studied

- Lung Cancer Stage III
- Lung Cancer Stage IV

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05996263
- **Lead sponsor:** University Hospital, Brest
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08-01
- **Primary completion:** 2023-08-31
- **Final completion:** 2024-08-31
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05996263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05996263, "Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05996263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*